CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
Rhea-AI Summary
CASI Pharmaceuticals (NASDAQ:CASI), a clinical-stage biopharmaceutical company specializing in therapies for organ transplant rejection and autoimmune diseases, has announced its participation in the upcoming Cantor Global Healthcare Conference.
CEO David Cory will engage in a fireside chat on September 3, 2025, at 11:30 AM ET in New York City. The company will also conduct one-on-one investor meetings during the conference. Investors can access the live webcast through CASI's website, with a replay available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CASI gained 9.42%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $38M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.
A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
When is CASI Pharmaceuticals (CASI) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access CASI Pharmaceuticals' presentation at the Cantor Conference?
What type of meetings will CASI Pharmaceuticals host at the Cantor Healthcare Conference?
What is CASI Pharmaceuticals' main business focus?
